卫材 英语是什么意思 - 英语翻译

• eisai

在 中文 中使用 卫材 的示例及其翻译为 英语

机构卫材.
The Agency Eisai.

绿茶是由一位名叫卫材的禅宗僧人从中国带到日本的。
Green Tea was brought from China to Japan by a Zen Monk called Eisai.

这是Biogen和卫材在2019年停止的第二项药物研究；.
This is the second drug study that Biogen and Eisai stopped in 2019;

卫材正在与全球分销合作伙伴讨论这个问题。
Eisai is having discussions with its global distribution partners regarding this issue.

这是Biogen和卫材在2019年中止的第二项药物研讨；.
This is the second drug study that Biogen and Eisai stopped in 2019;

卫材中国将相继推出在中枢神经领域和肿瘤领域的新产品。
Eisai China will launch successively new products in the fields of neurology and oncology.

在1214年，卫材的恶作剧继续由他向武士引入茶。
In 1214 Eisai's escapades continued by him introducing tea to the Samurai.

卫材和百健目前正在与监管机构讨论BAN2401的后续步骤。
Eisai and Biogen are currently discussing the next steps for BAN2401 with regulatory authorities.

目前，卫材在中国的总注册资本为10854万美金。
Currently, the total registered capital of Eisai China is USD 108.54 million.

卫材和渤健目前正在与监管机构探讨BAN2401的下一步计划。
Eisai and Biogen are currently discussing the next steps for BAN2401 with regulatory authorities.

希森美康和卫材强强联手，旨在催生一个通过血液样本来诊断AD的简单方法。
Sysmex and Eisai are engaged in joint development aimed at creating a simple method of diagnosing AD from a blood sample.

卫材集团将在全球独立开展Lemborexant的开发和商业化。
Eisai group will solely conduct the development and the commercialization of lemborexant globally.

今年3月，卫材与默沙东达成全球战略合作，共同开发和商业化Lenvima。
In March of this year, Eisai and Merck reached a global strategic cooperation to jointly develop and commercialize Lenvima.

卫材开发该制剂，是为了让服用片剂有困难的儿童和患者更容易服用Fycompa。
Eisai developed this formulation to make it easier to administer Fycompa to children and patients who have difficulty taking tablets.

根据协议，卫材将获得沙芬酰胺在日本的独家销售权和亚洲（七个国家*）的独家开发和销售权。
Under the agreement, Eisai will obtain exclusive rights to safinamide to market in Japan and to develop and market in Asia(seven countries*).

卫材和ImbriumTherapeutics致力于满足新兴的医疗需求，并改善患者及其家人的生活。
Eisai and Imbrium Therapeutics are striving to address new unmet medical needs and to improve the lives of patients and their families.

基于关心人类健康(hhc)理念，卫材致力于为发展中国家和新兴国家人民的健康和福祉做出贡献。
Under its human health care(hhc) philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries.

同时，卫材将进行临床试验以征求监管部门批准，并在亚洲进行申请。
Meanwhile, Eisai will conduct clinical trials for seeking regulatory approval, and make the applications in Asia.

BAN2401是一种用于治疗阿尔茨海默病的人源化单克隆抗体，是卫材与BioArctic战略研究联盟的研究成果。
BAN2401 is a humanized monoclonal antibody for Alzheimer's disease that is the result of a strategic research alliance between BioArctic and Eisai.

目前卫材和渤健(Biogen)正在针对Aducanumab进行两个III期临床研究(ENGAGE/EMERGE)。
Currently, Eisai and Biogen are advancing two Phase III clinical studies(ENGAGE/EMERGE) on aducanumab.

年2月，希森美康和卫材签署了一项全面的非排他性协议，旨在为痴呆领域开发新的诊断性测试方法。
In February 2016, Sysmex and Eisai signed a comprehensive non-exclusive agreement aimed at the development of new diagnostic tests in the field of dementia.

因此，卫材和默克承诺共同努力，确保欧洲各地的患者能够迅速获得Lenvatinib。
Eisai and Merck are therefore committed to working together to ensure that patients have rapid access to LENVIMA across Europe.”.

但直到公元1191年，太阳并没有真正崛起于日本绿茶的世界，当时另一位名叫卫材的佛教僧侣普及了喝绿茶以保持身体健康的想法。
But its full potential was not realised until 1191 CE, when another Buddhist monk named Eisai popularised the idea of drinking Green Tea for good health.

据说，卫材是第一个以粉末形式试验绿茶的人，这项实验最终风靡全球。
It is said that Eisai was the first to experiment with Green Tea in powder form, an experiment that eventually took the world by storm.

卫材将从这些Ricchi中发现具有新靶点和作用机制的创新新药，并致力于为治疗癌症做出贡献。
Eisai will discover innovative new drug with new target and mechanism of action from these Ricchi, and aims for contribution to cure cancers.

年3月，卫材与渤健（Biogen）就BAN2401签订了一份联合开发和商业化协议，并于2017年10月对该协议进行了修订。
In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401 and the parties amended that agreement in October 2017.

卫材及其公司集团将全球环境保护作为业务经营的重要部分，并且努力保护环境。
Eisai and its group of companies place global environmental protection as an important component of business operations and strive to maintain the environment.”.

卫材将在获得上市许可后接受Elenbecestat和BAN2401的所有销售预订并进行发布，并且两家公司将均享利润。
Eisai will book all sales for elenbecestat and BAN2401 following marketing approval and launch, and profits will be equally shared between the companies.

卫材和Sysmex已于2016年2月签订了一项全面的非排他性合作协议，旨在为痴呆领域创建新的诊断工具。
In February 2016, Sysmex and Eisai signed a comprehensive non-exclusive comprehensive agreement aimed at the creation of new diagnostics in the field of dementia.

卫材和Sysmex已于2016年2月签订了一项全面的非排他性合作协议，旨在为痴呆领域创建新的诊断工具。
Eisai and Sysmex have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia in February, 2016.